Drugs that contain Ozanimod Hydrochloride
1. List of Zeposia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8481573 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
| US8796318 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9382217 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
| US10239846 | CELGENE INTL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | May 27, 2024 |
| New Chemical Entity Exclusivity (NCE) | Mar 25, 2025 |
NCE-1 date: March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis
Dosage: CAPSULE;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic